RedHill Biopharma Business Summary

RedHill Biopharma Ltd. (RDHL) is a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary therapeutics for gastrointestinal (GI) and infectious diseases. The company generates revenue through a hybrid model of direct product sales, licensing agreements, and strategic collaborations. Its commercial portfolio is anchored by two FDA-approved products: Talicia®, a first-line treatment for H. pylori infection, and Aemcolo®, an oral antibiotic for travelers’ diarrhea. RedHill also maintains a late-stage clinical pipeline featuring opaganib for oncology and viral indications, RHB-107 for COVID-19 and other inflammatory diseases, and RHB-102 for GI-related side effects of GLP-1 therapies. In the competitive GI landscape, RedHill contends with Phathom Pharmaceuticals, Ironwood Pharmaceuticals, and Bausch Health (Salix), positioning itself as a niche specialist focused on high-unmet-need infectious GI conditions and host-directed antiviral therapies. RedHill was co-founded by CEO and Chairman Dror Ben-Asher and Ori Shilo, with Ben-Asher bringing a background in corporate finance from ProSeed Capital and academic pedigree from Oxford and Harvard. The executive team includes CFO Razi Ingber, a former PwC manager; COO Gilead Raday, who previously led Sepal Pharma; and Chief Commercial Officer Rick D. Scruggs, a former Executive VP at Salix Pharmaceuticals. Scientific leadership is provided by Chief Scientific Officer Mark L. Levitt, a board-certified oncologist with experience at Teva and the NCI, and Senior VP of R&D Reza Fathi. The company is backed by notable institutional investors including OrbiMed, Heights Capital Management, and SBI Holdings, and recently secured a strategic investment from Cumberland Pharmaceuticals in late 2025. The Board of Directors features industry veterans such as Dr. Kenneth Reed and Dr. Shmuel Cabilly, a co-inventor of fundamental antibody production technology.